Welcome to our dedicated page for Basel Medical Group SEC filings (Ticker: BMGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Basel Medical Group Ltd filings document its foreign private issuer reporting, Nasdaq listing-rule compliance, governance changes and corporate transactions. Form 6-K current reports cover periodic-filing compliance, minimum bid price notifications, board and executive appointments or resignations, and changes in the company's independent registered public accounting firm.
The company's SEC disclosures also record financing-related lock-up waivers, Form 20-F reporting matters, and the completed acquisition of Bethesda Medical as a wholly owned indirect subsidiary. These filings provide formal disclosure on the company's Singapore healthcare operations, capital-structure actions, audit oversight, governance structure and material events affecting its listed ordinary shares.
Basel Medical Group Ltd reports that interim CFO Neo Alton Chun How has filed an initial statement of beneficial ownership as an officer of the company. The report shows no recorded transactions, acquisitions, dispositions, or holdings entries for the issuer’s securities in this filing.
Basel Medical Group Ltd reports that Nasdaq has notified the company it has regained compliance with Nasdaq’s minimum bid price rule. The ordinary shares closed at $1.00 per share or greater for 10 consecutive business days from June 23, 2026 to July 7, 2026, satisfying Nasdaq Listing Rule 5550(a)(2) after a prior deficiency notice issued on January 22, 2026.
The company continues to operate a network of medical clinics in Singapore focused on orthopedic, trauma, neurosurgical and general medical services, serving corporate and individual clients across multiple locations.
Basel Medical Group Ltd reported unaudited results for the six months from July 1 to December 31, 2025, showing a return to profitability. Revenue from medical services was $6,428,419 (S$8,266,304), compared with S$5,034,080 in the prior comparable period. Profit after tax was $124,782, versus a prior loss of S$317,031, and total comprehensive income reached $373,216.
Total assets were $15,614,540 and total liabilities $10,576,376, leaving equity of $5,038,164 as of December 31, 2025. Operating cash flow was negative at $(1,275,665), and cash and cash equivalents declined to $1,044,640. The group added a new S$3,000,000 term loan and expanded its clinic network through several acquisitions and new subsidiaries.
The financial statements are prepared under IFRS, and management explicitly states that the group’s ability to continue as a going concern depends on continued financial support from its major shareholder, achieving sustainable operating profits and cash flows over the next 12 months, and securing additional financing and support from existing financiers.
Basel Medical Group Ltd is carrying out a 1-for-12 reverse share split of its ordinary shares, effective with Nasdaq trading on June 22, 2026. This is intended to help the company re-comply with Nasdaq’s minimum $1.00 bid price requirement under Marketplace Rule 5550(a)(2).
Every 12 existing ordinary shares will automatically combine into one share without any action by shareholders. The number of issued and outstanding ordinary shares will be reduced from 18,785,750 as of June 10, 2026 to approximately 1,565,480, subject to rounding. No fractional shares will be issued; instead, each shareholder will receive one whole share in place of any fractional share.
Basel Medical Group Ltd has appointed Mr. Neo Chun How Alton as its new interim Chief Financial Officer, effective June 2, 2026. He replaces Ms. Jianing Lu, who resigned as CFO, with the Board expressing appreciation for her service.
Mr. Neo brings experience in corporate leadership, financial management, and education. He previously served as deputy CEO of InCorp Global’s Singapore operations, worked on tax policy at Singapore’s Ministry of Finance, helped develop the Singapore Chartered Accountant Qualification Programme, and teaches accounting-related courses at tertiary institutions. He holds an MBA from the University of Hull and multiple professional accounting and valuation memberships.
Basel Medical Group Ltd director Soong Kwek Yoon has filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and not a ten percent owner, and does not report any transactions in company securities.
Basel Medical Group Ltd Chief Financial Officer Lu Jianing JN has filed an initial insider ownership report on Form 3. The filing lists no buy or sell transactions, and shows no derivative securities positions reported for this insider at this time.
Basel Medical Group Ltd director Tony Chen filed an initial Form 3 statement of beneficial ownership. The filing lists him as a director of BMGL but shows no reported transactions or derivative positions in this data, indicating only an initial disclosure of insider status.
Basel Medical Group Ltd Chief Executive Officer Chhoa Darren Yen Feng has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing excerpt shows no reported transactions and no listed derivative positions for the reporting person.
Basel Medical Group Ltd director and Chief Commercial Officer Tan Boon Chye (Darren) filed an initial ownership report showing indirect holdings in the company’s ordinary shares. A Singapore variable capital company, Rainforest Capital VCC, holds 10,205,229 ordinary shares on behalf of four subfunds.
One subfund, Basel Medical Fund, lists Tan Boon Chye as an ultimate beneficial owner, so he may be deemed to beneficially own a portion of these shares. He expressly disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest, and the filing does not report any new purchase or sale.